Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 153

Sort by

Sort Order Select

Journal Articles

Interaction between Presenting Features, Co-Occurring Mutations, MRD and Induction Treatment Influences Outcome in Adults with NPM1 Mutated AML - an Analysis of 1357 Patients in the UK NCRI AML17 and AML19 Studies

Blood (2023) 142 (Supplement 1): 2939.

https://doi.org/10.1182/blood-2023-179036

Published: 2023

Journal Articles

A Randomised Evaluation of Low-Dose Cytarabine Arabinoside Plus Lenalidomide Versus Single-Agent Low-Dose Cytarabine Arabinoside in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial

Mhairi Copland, Cono Ariti, Ian Thomas, Laura Upton, Mia Sydenham, Priyanka Mehta, Shahidul Islam, Lars Kjeldsen, Alan K. Burnett, Robert Hills, Nigel H. Russell, Mike Dennis

Blood (2021) 138 (Supplement 1): 1266.

https://doi.org/10.1182/blood-2021-147802

Published: 2021

Journal Articles

A Randomised Evaluation of Low-Dose Ara-C Plus BCT-100 Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial

Francis J. Mussai, Ian Thomas, Cono Ariti, Laura Upton, Mia Sydenham, Alan K. Burnett, Steve Knapper, Priyanka Mehta, Mary Frances McMullin, Mhairi Copland, Nigel H. Russell, Robert Hills

Blood (2021) 138 (Supplement 1): 2355.

https://doi.org/10.1182/blood-2021-148323

Published: 2021

Journal Articles

Prediction of Early Mortality with Non-Intensive Acute Myeloid Leukemia (AML) Therapies: Analysis of 1336 Patients from MRC/NCRI and SWOG

Xu Wang, Ian Thomas, Cono Ariti, Mike Dennis, Priyanka Mehta, Nigel H Russel, Mia Sydenham, Robert Hills, Alan K. Burnett, Sucha Nand, Sarit Assouline, Laura C. Michaelis, Harry P. Erba, Kathleen Kerr, Roland B. Walter, Megan Othus

Blood (2021) 138 (Supplement 1): 220.

https://doi.org/10.1182/blood-2021-151597

Published: 2021

Journal Articles

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

Blood (2019) 133 (15): 1630–1643.

https://doi.org/10.1182/blood-2019-01-894980

Published: 2019

Journal Articles

The Achievement of Complete Remission Is Associated with Improved Quality of Life in Non-Intensively Treated Patients with Acute Myeloid Leukemia: Results of the UK NCRI LI-1 Tria

Robert K. Hills, MA,DPhil,MSc, Ian Thomas, Alan K. Burnett, MD, Claire Jane Hemmaway, MD, Helen Dignum, Nigel H. Russell, Michael Dennis, MDMRCP,FRCPath

Blood (2018) 132 (Supplement 1): 372.

https://doi.org/10.1182/blood-2018-99-116173

Published: 2018

Journal Articles

Outcomes of Relapsed/Refractory Patients with IDH1/2 Mutated AML Treated with Non-Targeted Therapy: Results from the NCRI AML Trials

Robert K. Hills, MA,DPhil,MSc, Rosemary Gale, PhD, David C. Linch, Brian J.P Huntly, Elli Papaemmanuil, PhD, Paresh Vyas, Alan K. Burnett, MD, Nigel H. Russell

Blood (2018) 132 (Supplement 1): 664.

https://doi.org/10.1182/blood-2018-99-116482

Published: 2018

Journal Articles

Pre-Transplant NPM1 Mutant Transcript Level Is Highly Predictive of Outcome after Allograft and Thresholds Are Dependent on FLT3 ITD Status

Richard Dillon, MA, PhD MRCP, FRCPath, Robert K. Hills, MA, DPhil, MSc, Sylvie D Freeman, MBChB, DPhil, Nicola Potter, PhD, Adam Ivey, BSc, MSc, PhD, Jelena Jovanovic, PhD, Anju Kanda, MSc, Manohursingh Runglall, MSc, Nicola Foot, MSc, Laura Upton, Asim Khwaja, MD PhD, Jamie Cavenagh, MD PhD, Ruth Spearing, MD, Alan K. Burnett, MD, Nigel H. Russell, David Grimwade, PhD MRCP, MRCPath

Blood (2018) 132 (Supplement 1): 2739.

https://doi.org/10.1182/blood-2018-99-113662

Published: 2018

Journal Articles

Outcomes in Relapsed/Refractory Patients with FLT3-ITD Mutated AML Are Poor When Treated with Non-Targeted Therapy with a Potential Role for Stem Cell Transplantation: Results from the NCRI AML Trials

Robert K. Hills, MA,DPhil,MSc, Alan K. Burnett, MD, Rosemary Gale, PhD, David C. Linch, Amanda Gilkes, Nigel H. Russell

Blood (2018) 132 (Supplement 1): 1392.

https://doi.org/10.1182/blood-2018-99-116542

Published: 2018

Journal Articles

No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials

Rosemary E. Gale, Teodora Popa, Melissa Wright, Naeem Khan, Sylvie D. Freeman, Alan K. Burnett, Nigel H. Russell, Robert K. Hills, David C. Linch

Blood (2018) 131 (4): 468–471.

https://doi.org/10.1182/blood-2017-08-802157

Published: 2018

Includes: Supplemental data

Journal Articles

A Knowledge-Based Approach for Clinical Annotation of Oncogenic Variants to Support Patient-Tailored Diagnosis in Myeloid Disease

Blood (2017) 130 (Supplement 1): 1414.

https://doi.org/10.1182/blood.V130.Suppl_1.1414.1414

Published: 2017

Journal Articles

Characteristics and Outcome of Patients with Acute Myeloid Leukemia and t(6;9)(p22;q34)

Blood (2017) 130 (Supplement 1): 3906.

https://doi.org/10.1182/blood.V130.Suppl_1.3906.3906

Published: 2017

Journal Articles

An Evaluation of 17 Years of Low Dose Cytarabine As Therapy for AML Patients Not Fit for Intensive Treatment, Including Patients with Adverse Cytogenetics, Shows Improving Survival, Potential Underutilisation and Highlights the Need for New Therapy

Michael Dennis, MDMRCP,FRCPath, Robert K. Hills, DPhil, Nigel H. Russell, Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Ian Thomas, Mary Frances Frances McMullin, MB,Bch BAO, MD FRCPath, Sahra Ali, Alan K. Burnett, MD

Blood (2017) 130 (Supplement 1): 3874.

https://doi.org/10.1182/blood.V130.Suppl_1.3874.3874

Published: 2017

Journal Articles

Flow Cytometric Minimal Residual Disease As Risk Stratification Tool in Younger Adults with NPM1 Wild Type Standard Risk Acute Myeloid Leukemia

Sylvie D Freeman, MBChB, DPhil, Robert K. Hills, DPhil, Paul Virgo, Naeem Khan, PhD, Stephen Couzens, Richard James Dillon, MA, PhD MRCP, FRCPath, Laura Upton, Lars Kjeldsen, MD, Ian Thomas, David Grimwade, Alan K. Burnett, MD, Nigel H. Russell

Blood (2017) 130 (Supplement 1): 468.

https://doi.org/10.1182/blood.V130.Suppl_1.468.468

Published: 2017

Journal Articles

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML

Steven Knapper, Nigel Russell, Amanda Gilkes, Robert K. Hills, Rosemary E. Gale, James D. Cavenagh, Gail Jones, Lars Kjeldsen, Michael R. Grunwald, Ian Thomas, Heiko Konig, Mark J. Levis, Alan K. Burnett

Blood (2017) 129 (9): 1143–1154.

https://doi.org/10.1182/blood-2016-07-730648

Published: 2017

Includes: Supplemental data

Journal Articles

A Randomised Assessment of Ganetespib Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results of the LI-1 Trial

Michael Dennis, FRCPath, Robert K Hills, DPhil, Ian Thomas, Sunil Gupta, MBBS, MRCP, FRCPath, Nicki Panoskaltsis, MD, Mhairi Copland, PhD BSc, MB, ChB, MRCP, FRCPath, Alan K. Burnett, MD FRCP, Nigel H Russell, MD

Blood (2016) 128 (22): 2827.

https://doi.org/10.1182/blood.V128.22.2827.2827

Published: 2016

Journal Articles

Long Term Follow up from the NCRI AML17 Trial of Attenuated Arsenic Trioxide and ATRA Therapy for Newly Diagnosed and Relapsed Acute Promyelocytic Leukaemia

Nigel H Russell, MD, Alan K. Burnett, MD FRCP, Robert K Hills, DPhil, Sophie Betteridge, PhD, Michael Dennis, FRCPath, Richard Dillon, MA, MRCP, FRCPath, David Grimwade, PhD FRCPath

Blood (2016) 128 (22): 897.

https://doi.org/10.1182/blood.V128.22.897.897

Published: 2016

Journal Articles

Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia

Alan K. Burnett, Nigel H. Russell, Robert K. Hills

Blood (2016) 128 (3): 449–452.

https://doi.org/10.1182/blood-2016-04-712091

Published: 2016

Journal Articles

Quizartinib Significantly Improves Overall Survival in FLT3-ITD Positive AML Patients Relapsed after Stem Cell Transplantation or after Failure of Salvage Chemotherapy: A Comparison with Historical AML Database (UK NCRI data)

Robert K Hills, DPhil, Guy Gammon, MBBS,MRCP, Denise Trone, Alan K. Burnett, MD FRCP

Blood (2015) 126 (23): 2557.

https://doi.org/10.1182/blood.V126.23.2557.2557

Published: 2015

Journal Articles

HFE Gene Mutation Status Predicts Response to Gemtuzumab Ozogamicin in AML

Etienne Paubelle, Alice Marceau, Florence Zylbersztejn, Mickael Dussiot, Ivan Cruz Moura, PhD, Pascale Cornillet-Lefebvre, MD, Jacques Delaunay, MD, Alan K. Burnett, Sylvie Castaigne, Philippe Guardiola, MD, Norbert Ifrah, MD PhD, Hervé Dombret, Claude Preudhomme, Robert K Hills, DPhil, Olivier Hermine

Blood (2015) 126 (23): 1307.

https://doi.org/10.1182/blood.V126.23.1307.1307

Published: 2015

NARROW

Interaction between Presenting Features, Co-Occurring Mutations, MRD and Induction Treatment Influences Outcome in Adults with NPM1 Mutated AML - an Analysis of 1357 Patients in the UK NCRI AML17 and AML19 Studies

A Randomised Evaluation of Low-Dose Cytarabine Arabinoside Plus Lenalidomide Versus Single-Agent Low-Dose Cytarabine Arabinoside in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial

A Randomised Evaluation of Low-Dose Ara-C Plus BCT-100 Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results from the LI-1 Trial

Prediction of Early Mortality with Non-Intensive Acute Myeloid Leukemia (AML) Therapies: Analysis of 1336 Patients from MRC/NCRI and SWOG

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet

The Achievement of Complete Remission Is Associated with Improved Quality of Life in Non-Intensively Treated Patients with Acute Myeloid Leukemia: Results of the UK NCRI LI-1 Tria

Outcomes of Relapsed/Refractory Patients with IDH1/2 Mutated AML Treated with Non-Targeted Therapy: Results from the NCRI AML Trials

Pre-Transplant NPM1 Mutant Transcript Level Is Highly Predictive of Outcome after Allograft and Thresholds Are Dependent on FLT3 ITD Status

Outcomes in Relapsed/Refractory Patients with FLT3-ITD Mutated AML Are Poor When Treated with Non-Targeted Therapy with a Potential Role for Stem Cell Transplantation: Results from the NCRI AML Trials

No evidence that CD33 splicing SNP impacts the response to GO in younger adults with AML treated on UK MRC/NCRI trials

A Knowledge-Based Approach for Clinical Annotation of Oncogenic Variants to Support Patient-Tailored Diagnosis in Myeloid Disease

Characteristics and Outcome of Patients with Acute Myeloid Leukemia and t(6;9)(p22;q34)

An Evaluation of 17 Years of Low Dose Cytarabine As Therapy for AML Patients Not Fit for Intensive Treatment, Including Patients with Adverse Cytogenetics, Shows Improving Survival, Potential Underutilisation and Highlights the Need for New Therapy

Flow Cytometric Minimal Residual Disease As Risk Stratification Tool in Younger Adults with NPM1 Wild Type Standard Risk Acute Myeloid Leukemia

A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML

A Randomised Assessment of Ganetespib Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia: Results of the LI-1 Trial

Long Term Follow up from the NCRI AML17 Trial of Attenuated Arsenic Trioxide and ATRA Therapy for Newly Diagnosed and Relapsed Acute Promyelocytic Leukaemia

Higher daunorubicin exposure benefits FLT3 mutated acute myeloid leukemia

Quizartinib Significantly Improves Overall Survival in FLT3-ITD Positive AML Patients Relapsed after Stem Cell Transplantation or after Failure of Salvage Chemotherapy: A Comparison with Historical AML Database (UK NCRI data)

HFE Gene Mutation Status Predicts Response to Gemtuzumab Ozogamicin in AML

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only